Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Mersana Therapeutics Is Sinking Today

By Cory Renauer - Mar 31, 2020 at 3:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clinical-trial results from the company's first proof-of-concept study were disappointing.

What happened

Shares of Mersana Therapeutics (MRSN 2.08%), a clinical-stage biopharmaceutical company, are falling after the company released clinical-trial results for its lead candidate. Investors weren't thrilled with the data and pushed the stock 14.9% lower as of 3:13 p.m. EST on Tuesday.

So what 

Mersana's stock price has been erratic as investors, agitated by the coronavirus pandemic, waited for phase 1 data from the company's new lead candidate, XMT-1536. That's why results that weren't great were enough to push the stock lower today.

Person holding a downward sloping arrow.

Image source: Getty Images.

The company abandoned its previous lead candidate, XMT-1522, after a disappointing risk-to-benefit ratio in a phase 1 study with breast cancer patients led Mersana's former collaboration-partner Takeda to walk away from the program.

Since the company's fallout with Takeda, investors were easily frightened by less-than-encouraging safety and efficacy data that the company presented from a phase 1 ascending-dose study with XMT-1536 and patients with a variety of solid tumors. The trial included 59 patients treated with seven ascending dosages of XMT-1536, an antibody that releases a small dose of lethal chemotherapy when it encounters cells with a surface protein called NaPi2b.

The stock is getting pressured today because none of the patients treated with XMT-1536 achieved complete remission, and it looks like the drug shrank tumors for just five patients. Moreover, just two of those partial responses are ongoing.

Now what

Mersana did its best to focus on arguably positive signals that aren't going to persuade any deep-pocketed drugmakers like Takeda back to the deal table. That won't stop the company from enrolling another 90 patients into the study, and Mersana expects to provide interim data from the expansion portion in the second quarter.

Until Mersana can show stronger signals of efficacy for one of its novel new cancer drug candidates, investors should probably watch the company's story unfold from a safe distance.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mersana Therapeutics, Inc. Stock Quote
Mersana Therapeutics, Inc.
MRSN
$7.38 (2.08%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.